QQQ   438.70 (+0.79%)
AAPL   180.36 (-0.58%)
MSFT   410.03 (+0.57%)
META   489.25 (+1.08%)
GOOGL   137.36 (+0.72%)
AMZN   175.23 (+1.20%)
TSLA   200.19 (-0.92%)
NVDA   793.56 (+2.18%)
NIO   5.67 (+4.42%)
AMD   190.97 (+8.17%)
BABA   74.18 (-0.55%)
T   17.01 (+0.29%)
F   12.42 (+0.98%)
MU   90.22 (+0.57%)
CGC   3.27 (-2.68%)
GE   156.23 (+0.40%)
DIS   111.20 (+0.36%)
AMC   4.29 (-14.03%)
PFE   26.79 (-0.92%)
PYPL   60.29 (+0.07%)
XOM   104.66 (+0.33%)
QQQ   438.70 (+0.79%)
AAPL   180.36 (-0.58%)
MSFT   410.03 (+0.57%)
META   489.25 (+1.08%)
GOOGL   137.36 (+0.72%)
AMZN   175.23 (+1.20%)
TSLA   200.19 (-0.92%)
NVDA   793.56 (+2.18%)
NIO   5.67 (+4.42%)
AMD   190.97 (+8.17%)
BABA   74.18 (-0.55%)
T   17.01 (+0.29%)
F   12.42 (+0.98%)
MU   90.22 (+0.57%)
CGC   3.27 (-2.68%)
GE   156.23 (+0.40%)
DIS   111.20 (+0.36%)
AMC   4.29 (-14.03%)
PFE   26.79 (-0.92%)
PYPL   60.29 (+0.07%)
XOM   104.66 (+0.33%)
QQQ   438.70 (+0.79%)
AAPL   180.36 (-0.58%)
MSFT   410.03 (+0.57%)
META   489.25 (+1.08%)
GOOGL   137.36 (+0.72%)
AMZN   175.23 (+1.20%)
TSLA   200.19 (-0.92%)
NVDA   793.56 (+2.18%)
NIO   5.67 (+4.42%)
AMD   190.97 (+8.17%)
BABA   74.18 (-0.55%)
T   17.01 (+0.29%)
F   12.42 (+0.98%)
MU   90.22 (+0.57%)
CGC   3.27 (-2.68%)
GE   156.23 (+0.40%)
DIS   111.20 (+0.36%)
AMC   4.29 (-14.03%)
PFE   26.79 (-0.92%)
PYPL   60.29 (+0.07%)
XOM   104.66 (+0.33%)
QQQ   438.70 (+0.79%)
AAPL   180.36 (-0.58%)
MSFT   410.03 (+0.57%)
META   489.25 (+1.08%)
GOOGL   137.36 (+0.72%)
AMZN   175.23 (+1.20%)
TSLA   200.19 (-0.92%)
NVDA   793.56 (+2.18%)
NIO   5.67 (+4.42%)
AMD   190.97 (+8.17%)
BABA   74.18 (-0.55%)
T   17.01 (+0.29%)
F   12.42 (+0.98%)
MU   90.22 (+0.57%)
CGC   3.27 (-2.68%)
GE   156.23 (+0.40%)
DIS   111.20 (+0.36%)
AMC   4.29 (-14.03%)
PFE   26.79 (-0.92%)
PYPL   60.29 (+0.07%)
XOM   104.66 (+0.33%)

7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

 
One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that are ready to make strong moves forward in 2022.

Click the "Continue to Slide #1" button to view the first company.